{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:42:21Z","timestamp":1794048141349,"version":"4.8.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Behavioral and psychological symptoms of dementia significantly impact patient outcomes, caregiver burden, and healthcare costs. Current pharmacologic treatments are limited by efficacy and safety concerns. Cobenfy, a novel combination of xanomeline and trospium chloride, has shown efficacy in schizophrenia and presents a promising alternative for treating behavioral and psychological symptoms of dementia. This editorial explores the potential role of Cobenfy in the management of behavioral and psychological symptoms of dementia. To date, no trials of Cobenfy for behavioral and psychological symptoms of dementia have been completed; however, multiple trials are underway to investigate this medication for psychosis and agitation in Alzheimer\u2019s disease. Cobenfy may offer a safer pharmacologic option for behavioral and psychological symptoms of dementia compared with existing treatments. Further research in older adult populations is warranted.<\/jats:p>","DOI":"10.1177\/03000605261417092","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:33:32Z","timestamp":1769855612000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["From schizophrenia to dementia: Is Cobenfy a potential treatment for behavioral and psychological symptoms of dementia?"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7114-7084","authenticated-orcid":false,"given":"Julia C","family":"Golden","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla S","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern Medical Center, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-2794","authenticated-orcid":false,"given":"Rajesh R","family":"Tampi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Creighton University, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220508"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-022-01347-y"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610217001879"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.490"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000036904.73393.E4"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.01.017"},{"key":"e_1_3_6_8_2","first-page":"1","article-title":"An overview of the pathophysiology of agitation in Alzheimer\u2019s dementia with a focus on neurotransmitters and circuits","volume":"23","author":"Cummings JL","year":"2024","unstructured":"Cummings JL, Brubaker M, Selzler KJ, et\u00a0al. An overview of the pathophysiology of agitation in Alzheimer\u2019s dementia with a focus on neurotransmitters and circuits. CNS Spectr 2024; 23: 1\u201310.","journal-title":"CNS Spectr"},{"key":"e_1_3_6_9_2","first-page":"646","article-title":"Central serotonergic activity is related to the aggressive behaviors of Alzheimer\u2019s disease","volume":"27","author":"Lanct\u00f4t KL","year":"2002","unstructured":"Lanct\u00f4t KL, Herrmann N, Eryavec G, et\u00a0al. Central serotonergic activity is related to the aggressive behaviors of Alzheimer\u2019s disease. Neuropsychopharmacology 2002; 27: 646\u2013654.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.130"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12730"},{"key":"e_1_3_6_12_2","unstructured":"US Food and Drug Administration. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease (2023 accessed 28 August 2025)."},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"e_1_3_6_14_2","first-page":"CD008191","article-title":"Antidepressants for agitation and psychosis in dementia","volume":"2011","author":"Seitz DP","year":"2011","unstructured":"Seitz DP, Adunuri N, Gill SS, et\u00a0al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; 2011: CD008191.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035185"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-dn-2023-0007"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610223000091"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1017\/S104161022200103X"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113641"},{"key":"e_1_3_6_20_2","unstructured":"US Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics https:\/\/wayback.archive-it.org\/7993\/20170722190727\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm (2008 accessed 27 August 2025)."},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15668"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852925100424"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.006"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02190-6"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785"},{"key":"e_1_3_6_26_2","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb presents new long-term data from the EMERGENT program evaluating COBENFY\u2122 (xanomeline and trospium chloride) in adults with schizophrenia at Psych Congress https:\/\/news.bms.com\/news\/details\/2024\/Bristol-Myers-Squibb-Presents-New-Long-term-Data-from-the-EMERGENT-Program-Evaluating-COBENFY-xanomeline-and-trospium-chloride-in-Adults-with-Schizophrenia-at-Psych-Congress-2024\/default.aspx (2024 accessed 28 August 2025)."},{"key":"e_1_3_6_27_2","unstructured":"US Food and Drug Administration. Cobenfy (xanomeline and trospium chloride). Drug approval package 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216158s000lbl.pdf (2024 accessed 28 August 2025)."},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240076"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7058341"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16476-w"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00090a019"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1421554"},{"key":"e_1_3_6_34_2","unstructured":"Karuna Therapeutics. A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer\u2019s disease (ADEPT-1). ClinicalTrials.gov identifier NCT05511363 https:\/\/clinicaltrials.gov\/study\/NCT05511363 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_35_2","unstructured":"Karuna Therapeutics. A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer\u2019s disease (ADEPT-2). ClinicalTrials.gov identifier NCT06126224 https:\/\/clinicaltrials.gov\/study\/NCT06126224 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_36_2","unstructured":"Karuna Therapeutics. A phase\u202f3 global multicenter open-label extension study to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer\u2019s disease (ADEPT-3). ClinicalTrials.gov identifier NCT05980949 https:\/\/clinicaltrials.gov\/study\/NCT05980949 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_37_2","unstructured":"Karuna Pharmaceuticals. A phase\u202f3 randomized double-blind placebo-controlled parallel group study to evaluate the safety and efficacy of KarXT for the treatment of psychosis associated with Alzheimer\u2019s disease (ADEPT-4). ClinicalTrials.gov identifier NCT06585787 https:\/\/clinicaltrials.gov\/study\/NCT06585787 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_38_2","unstructured":"Bristol-Myers Squibb. A study to evaluate safety and efficacy of KarXT\u2009+\u2009KarX-EC as a treatment for psychosis associated with Alzheimer\u2019s disease (ADEPT-5). ClinicalTrials.gov identifier NCT06947941 https:\/\/clinicaltrials.gov\/study\/NCT06947941 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_39_2","unstructured":"Bristol-Myers Squibb. A phase\u202f3 randomized double-blind placebo-controlled parallel group study to evaluate the safety and efficacy of KarXT\u202f+\u202fKarX-EC for the treatment of agitation associated with Alzheimer\u2019s disease (ADAGIO-1). ClinicalTrials.gov identifier NCT07011732 https:\/\/clinicaltrials.gov\/study\/NCT07011732 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_40_2","unstructured":"Bristol-Myers Squibb. A phase\u202f3 randomized double-blind placebo-controlled parallel group study to evaluate the safety and efficacy of KarXT\u202f+\u202fKarX-EC for the treatment of agitation associated with Alzheimer\u2019s disease (ADAGIO-2). ClinicalTrials.gov identifier NCT07011745 https:\/\/clinicaltrials.gov\/study\/NCT07011745 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_41_2","unstructured":"Bristol-Myers Squibb. A study to evaluate the long-term efficacy and safety of KarXT\u202f+\u202fKarX-EC for agitation in Alzheimer\u2019s disease (ADAGIO-3). ClinicalTrials.gov identifier NCT06937229 https:\/\/clinicaltrials.gov\/study\/NCT06937229 (2025 accessed 28 August 2025)."},{"key":"e_1_3_6_42_2","doi-asserted-by":"crossref","unstructured":"Watson C Cummings JL Grossberg GT et\u00a0al. Evaluating KarXT (xanomeline\u2013trospium) as a treatment for psychosis associated with Alzheimer\u2019s disease: design of the phase 3 ADEPT-1 relapse prevention study. In: Alzheimer\u2019s Association International Conference Amsterdam Netherlands 16\u201320 July 2023.","DOI":"10.1017\/S1041610224002035"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261417092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261417092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261417092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:34Z","timestamp":1777459714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261417092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/03000605261417092"],"URL":"https:\/\/doi.org\/10.1177\/03000605261417092","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"03000605261417092"}}